China's Oncology Drug Harvest: Multiple Class 1 Innovative Therapies Win NMPA Approval in August

China's oncology drug pipeline is delivering. In what industry watchers are calling a banner year for domestic innovation, regulators approved a wave of homegrown Class 1 anticancer therapies in August alone—drugs targeting rare cancers and addressing unmet clinical needs that have long gone underserved.

The approvals signal a shift in the country's pharmaceutical ambitions. After years of building R&D muscle, Chinese drugmakers are moving up the value chain—competing not on volume, but on clinical differentiation and global relevance.

A Rare Biliary Cancer Gets a Targeted Option

Hutchison Meditech's fruquintinib tartrate tablets, marketed as Ailingda, received conditional approval from China's National Medical Products Administration (NMPA) through an expedited review pathway. The drug targets adult patients with advanced, metastatic, or unresectable intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements—a rare but aggressive form of bile duct cancer with limited treatment options.

The approval rests on data from a pivotal Phase II/IIIb registrational trial conducted in China. The confirmatory Phase IIIb cohort, which will further validate clinical benefit and safety, began enrolling patients in January 2026.

Beating Brain Metastases in Lung Cancer

On August 27, the NMPA conditionally approved TYK medicines' deuceronib mesylate tablets (TY-9591) for first-line treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 19 deletions or L858R mutations, with central nervous system metastases.

Deuceronib is a deuterium-optimized variant of osimertinib, designed to reduce toxic metabolite formation and deliver improved pharmacokinetic profiles. At the 2026 ASCO Annual Meeting, TYK medicines presented interim results from the Phase II ESAONA trial as a Late-Breaking Abstract oral presentation—and the data turned heads.

In the deuceronib arm, the intracranial objective response rate (iORR) reached 95.5%, compared with 79.6% in the osimertinib group (P=0.0004). Intracranial progression-free survival had not been reached in the deuceronib cohort at the time of analysis, versus 17.51 months in the osimertinib arm (hazard ratio 0.46).

For lung cancer patients, brain metastases remain one of the most difficult clinical challenges. A drug that penetrates the blood-brain barrier more effectively—and holds progression at bay—could reshape first-line treatment algorithms.

A New Option for Heavily Pretreated Myeloma Patients

Chongqing Genrix Biopharmaceutical's weilaituomumab injection (Weiketo) also secured NMPA approval on August 27. The Class 1 biologic targets adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Genrix has already licensed the asset beyond Greater China. Cullinan Therapeutics holds development, manufacturing, and commercialization rights for the drug outside the region. Within Greater China—including mainland China, Hong Kong, Macau, and Taiwan—Chongqing Yaoyou Pharmaceutical (Yaopharma) secured those same rights through a separate business development deal for the asset known as GR1803 injection.

The dual licensing structure reflects a broader trend: Chinese biotechs are no longer content with domestic markets alone. They are structuring deals that position their assets for global competition from day one.

From Volume to Value

The August approvals are not isolated events. They represent the maturation of a domestic innovation ecosystem that has spent the past decade building capabilities in target identification, clinical development, and regulatory engagement.

The competitive logic has shifted. It is no longer about how many drugs a company can file, but whether those drugs offer genuine clinical differentiation—and whether they can compete on the world stage.

For China's oncology pipeline, the harvest is here. The question now is how much of it will be consumed at home, and how much will flow abroad.